quantisnow
FeedTopReportsPricing
⌘K
Live feed
10:24:29·160d
ANALYSTRating
TScan Therapeutics Inc. logo

TScan Therapeutics downgraded by Morgan Stanley

TCRX· TScan Therapeutics Inc.
Health Care
Original source

Companies

  • TCRX
    TScan Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Nov 14UpdateMorgan Stanley-
  • May 16UpdateBTIG Research$12.00
  • May 13UpdateNeedham$11.00
  • Jun 22UpdateWedbush$8.00
  • Dec 16UpdateHC Wainwright & Co.$21.00
  • Aug 13UpdateCowen & Co.-

Related

  • SEC6d
    SEC Form DEF 14A filed by TScan Therapeutics Inc.
  • PR15d
    TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
  • SEC16d
    SEC Form PRE 14A filed by TScan Therapeutics Inc.
  • SEC21d
    SEC Form 8-K filed by TScan Therapeutics Inc.
  • PR35d
    Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
  • SEC50d
    SEC Form S-8 filed by TScan Therapeutics Inc.
  • SEC50d
    SEC Form 10-K filed by TScan Therapeutics Inc.
  • SEC50d
    TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022